Eli Lilly (LLY)
(Delayed Data from NYSE)
$764.71 USD
+16.52 (2.21%)
Updated Sep 16, 2025 03:59 PM ET
After-Market: $764.00 -0.71 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LLY 764.71 +16.52(2.21%)
Will LLY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
Why the Market Dipped But Eli Lilly (LLY) Gained Today
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Other News for LLY
Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing
Eli Lilly (LLY) Faces Investor Concerns Over Recent Trial Data
Eli Lilly's (LLY) Peresolimab Faces Efficacy Challenges in Rheumatoid Arthritis Treatment
Eli Lilly (LLY) Commits $5B to New Manufacturing Facility in Virginia
AnaptysBio falls after data abstract on Lilly’s peresolimab